Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib

Saved in:
Bibliographic Details
Published in:JAAD Case Reports Vol. 32; pp. 81 - 83
Main Authors: Nash, David, Kirchhof, Mark G.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.02.2023
Elsevier
Subjects:
ISSN:2352-5126, 2352-5126
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Author Kirchhof, Mark G.
Nash, David
Author_xml – sequence: 1
  givenname: David
  surname: Nash
  fullname: Nash, David
  organization: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
– sequence: 2
  givenname: Mark G.
  surname: Kirchhof
  fullname: Kirchhof, Mark G.
  email: mkirchho@uottawa.ca
  organization: Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36691588$$D View this record in MEDLINE/PubMed
BookMark eNqFkktv1DAUhS1UREvpH2CBsmQzwY_Y8SBUqYx4FFViAawtP25mnGbswU6K-u9xmBa1lSgrW_Y935HOuc_RQYgBEHpJcE0wEW_6unc21RRTWhNaYyyeoCPKOF1wQsXBnfshOsm5xxgT3rSsJc_QIRNiSbiUR2j1fhqGOOVqB9vdxq-jd9WYQI_gql9-3FRfdCi_lz7oDJUPG2_8GFM17bTT1o8-ePMCPe30kOHk5jxGPz5--L76vLj4-ul8dXaxsLyhYuGKu-TMiIY03ABjzBgtCCcdA-usxEQyzIiWElvnOkFs0wkjiRCaUk04O0bne66Lule75Lc6XauovfrzENNa6TR6O4DqOIjCaGgxapg2Zmm6xhrhOpDGwMw63bN2k9mCsxDGpId70Ps_wW_UOl6ppRQlyLYAXt8AUvw5QR7V1mcLw6ADlDwVbcWStbyVpIy-uuv11-S2hTIg9wM2xZwTdKokq0cfZ2s_KILV3Lnq1dy5mjtXhKrSeZHSB9Jb-qOid3sRlLauPCSVrYdgwfkEdixx-sflpw_kdih7YPVwCdeQ-zilUPZAEZWLQH2bN3FeREoxLis4B_L234D_uf8GpCTukQ
CitedBy_id crossref_primary_10_1111_jdv_20313
crossref_primary_10_3390_cancers17111845
crossref_primary_10_1177_12034754251351854
crossref_primary_10_1007_s13555_025_01444_9
crossref_primary_10_3389_fimmu_2024_1464474
crossref_primary_10_1016_j_jaad_2025_01_086
crossref_primary_10_1111_ajd_14389
crossref_primary_10_1155_dth_6185003
crossref_primary_10_3390_clinpract15050091
crossref_primary_10_1007_s40257_023_00832_1
crossref_primary_10_3389_fimmu_2023_1220887
crossref_primary_10_1093_bjd_ljaf219
crossref_primary_10_1007_s12325_024_02992_w
crossref_primary_10_1016_j_jdcr_2024_12_017
crossref_primary_10_3389_fimmu_2025_1537428
crossref_primary_10_3389_fimmu_2025_1563286
crossref_primary_10_1111_jdv_19475
crossref_primary_10_3389_fmed_2023_1196946
crossref_primary_10_1016_j_jaad_2023_02_015
Cites_doi 10.1001/jamadermatol.2021.3023
10.1590/abd1806-4841.20199007
10.1155/2017/6716419
10.1046/j.0022-202x.2001.01505.x
10.1016/j.jaad.2020.01.089
10.1111/dth.15754
10.1001/jamaophthalmol.2018.3789
ContentType Journal Article
Copyright 2022 American Academy of Dermatology, Inc.
American Academy of Dermatology, Inc.
2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access.. 2022 American Academy of Dermatology, Inc.
Copyright_xml – notice: 2022 American Academy of Dermatology, Inc.
– notice: American Academy of Dermatology, Inc.
– notice: 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access.. 2022 American Academy of Dermatology, Inc.
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1016/j.jdcr.2022.12.006
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2352-5126
EndPage 83
ExternalDocumentID oai_doaj_org_article_f5e6ddf425be43abb9bf4cb6dfe8bbe5
PMC9860157
36691588
10_1016_j_jdcr_2022_12_006
S2352512622005471
1_s2_0_S2352512622005471
Genre Case Reports
GroupedDBID .1-
.FO
0R~
1P~
4.4
457
53G
5VS
AAEDT
AAEDW
AAIKJ
AALRI
AAXUO
AAYWO
ABMAC
ACGFS
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEUPX
AEXQZ
AFJKZ
AFPUW
AFRHN
AFTJW
AGHFR
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APXCP
BAWUL
BCNDV
EBS
EJD
FDB
GROUPED_DOAJ
HYE
IPNFZ
IXB
KQ8
M41
M~E
O9-
OK1
RIG
ROL
RPM
SSZ
Z5R
0SF
6I.
AACTN
AAFTH
AFCTW
NCXOZ
ABMYL
AAYXX
CITATION
NPM
7X8
5PM
ID FETCH-LOGICAL-c5426-d473853b64145be333bba6151f3ecdc80183031a880cddf61c4f6b8166a22a153
IEDL.DBID DOA
ISSN 2352-5126
IngestDate Fri Oct 03 12:50:21 EDT 2025
Thu Aug 21 18:38:51 EDT 2025
Thu Oct 02 11:46:49 EDT 2025
Thu Jan 02 22:52:10 EST 2025
Thu Nov 13 04:19:08 EST 2025
Tue Nov 18 21:09:00 EST 2025
Sat Mar 16 16:14:11 EDT 2024
Tue Feb 25 20:12:41 EST 2025
Tue Aug 26 16:31:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords upadacitinib
treatment
bullous pemphigoid
STAT
AD
IL
JAK
JAK inhibition
BP
atopic dermatitis
signal transducers and activators of transcription
Janus kinase
interleukin
BP, bullous pemphigoid
STAT, signal transducers and activators of transcription
JAK, Janus kinase
IL, interleukin
AD, atopic dermatitis
Language English
License This is an open access article under the CC BY-NC-ND license.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5426-d473853b64145be333bba6151f3ecdc80183031a880cddf61c4f6b8166a22a153
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
OpenAccessLink https://doaj.org/article/f5e6ddf425be43abb9bf4cb6dfe8bbe5
PMID 36691588
PQID 2769375781
PQPubID 23479
PageCount 3
ParticipantIDs doaj_primary_oai_doaj_org_article_f5e6ddf425be43abb9bf4cb6dfe8bbe5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9860157
proquest_miscellaneous_2769375781
pubmed_primary_36691588
crossref_citationtrail_10_1016_j_jdcr_2022_12_006
crossref_primary_10_1016_j_jdcr_2022_12_006
elsevier_sciencedirect_doi_10_1016_j_jdcr_2022_12_006
elsevier_clinicalkeyesjournals_1_s2_0_S2352512622005471
elsevier_clinicalkey_doi_10_1016_j_jdcr_2022_12_006
PublicationCentury 2000
PublicationDate 2023-02-01
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JAAD Case Reports
PublicationTitleAlternate JAAD Case Rep
PublicationYear 2023
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Teraki, Hotta, Shiohara (bib5) 2001; 117
Juczynska, Wozniacka, Waszczykowska (bib9) 2017; 2017
Padda, Bhatt, Parmar (bib3) 2022
Blauvelt, Teixeira, Simpson (bib4) 2021; 157
James, Paley, Brasington, Custer, Margolis, Paley (bib7) 2021; 22
Sarny, Hucke, El-Shabrawi (bib10) 2018; 136
Abdat, Waldman, de Bedout (bib6) 2020; 83
Miyamoto, Santi, Aoki, Maruta (bib1) 2019; 94
Xiao, Xiang, Li (bib8) 2022; 35
Khalid, Khan, Ali, Almas, Khedro, Nagarajan (bib2) 2021; 70
Juczynska (10.1016/j.jdcr.2022.12.006_bib9) 2017; 2017
Abdat (10.1016/j.jdcr.2022.12.006_bib6) 2020; 83
Xiao (10.1016/j.jdcr.2022.12.006_bib8) 2022; 35
Blauvelt (10.1016/j.jdcr.2022.12.006_bib4) 2021; 157
Padda (10.1016/j.jdcr.2022.12.006_bib3) 2022
James (10.1016/j.jdcr.2022.12.006_bib7) 2021; 22
Teraki (10.1016/j.jdcr.2022.12.006_bib5) 2001; 117
Sarny (10.1016/j.jdcr.2022.12.006_bib10) 2018; 136
Miyamoto (10.1016/j.jdcr.2022.12.006_bib1) 2019; 94
Khalid (10.1016/j.jdcr.2022.12.006_bib2) 2021; 70
36822352 - J Am Acad Dermatol. 2023 May;88(5):1004
References_xml – volume: 35
  year: 2022
  ident: bib8
  article-title: Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib
  publication-title: Dermatol Ther
– volume: 2017
  year: 2017
  ident: bib9
  article-title: Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis
  publication-title: Mediators Inflamm
– volume: 70
  year: 2021
  ident: bib2
  article-title: A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions
  publication-title: Ann Med Surg (Lond)
– year: 2022
  ident: bib3
  publication-title: StatPearls
– volume: 22
  year: 2021
  ident: bib7
  article-title: Tofacitinib for refractory ocular mucous membrane pemphigoid
  publication-title: Am J Ophthalmol Case Rep
– volume: 83
  start-page: 46
  year: 2020
  end-page: 52
  ident: bib6
  article-title: Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series
  publication-title: J Am Acad Dermatol
– volume: 157
  start-page: 1047
  year: 2021
  end-page: 1055
  ident: bib4
  article-title: Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial
  publication-title: JAMA Dermatol
– volume: 136
  start-page: 1420
  year: 2018
  end-page: 1422
  ident: bib10
  article-title: Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib
  publication-title: JAMA Ophthalmol
– volume: 94
  start-page: 133
  year: 2019
  end-page: 146
  ident: bib1
  article-title: Bullous pemphigoid
  publication-title: An Bras Dermatol
– volume: 117
  start-page: 1097
  year: 2001
  end-page: 1102
  ident: bib5
  article-title: Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells
  publication-title: J Invest Dermatol
– volume: 157
  start-page: 1047
  issue: 9
  year: 2021
  ident: 10.1016/j.jdcr.2022.12.006_bib4
  article-title: Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2021.3023
– year: 2022
  ident: 10.1016/j.jdcr.2022.12.006_bib3
  article-title: Upadacitinib
– volume: 94
  start-page: 133
  issue: 2
  year: 2019
  ident: 10.1016/j.jdcr.2022.12.006_bib1
  article-title: Bullous pemphigoid
  publication-title: An Bras Dermatol
  doi: 10.1590/abd1806-4841.20199007
– volume: 70
  year: 2021
  ident: 10.1016/j.jdcr.2022.12.006_bib2
  article-title: A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions
  publication-title: Ann Med Surg (Lond)
– volume: 22
  year: 2021
  ident: 10.1016/j.jdcr.2022.12.006_bib7
  article-title: Tofacitinib for refractory ocular mucous membrane pemphigoid
  publication-title: Am J Ophthalmol Case Rep
– volume: 2017
  year: 2017
  ident: 10.1016/j.jdcr.2022.12.006_bib9
  article-title: Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis
  publication-title: Mediators Inflamm
  doi: 10.1155/2017/6716419
– volume: 117
  start-page: 1097
  issue: 5
  year: 2001
  ident: 10.1016/j.jdcr.2022.12.006_bib5
  article-title: Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells
  publication-title: J Invest Dermatol
  doi: 10.1046/j.0022-202x.2001.01505.x
– volume: 83
  start-page: 46
  issue: 1
  year: 2020
  ident: 10.1016/j.jdcr.2022.12.006_bib6
  article-title: Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series
  publication-title: J Am Acad Dermatol
  doi: 10.1016/j.jaad.2020.01.089
– volume: 35
  issue: 10
  year: 2022
  ident: 10.1016/j.jdcr.2022.12.006_bib8
  article-title: Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib
  publication-title: Dermatol Ther
  doi: 10.1111/dth.15754
– volume: 136
  start-page: 1420
  issue: 12
  year: 2018
  ident: 10.1016/j.jdcr.2022.12.006_bib10
  article-title: Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib
  publication-title: JAMA Ophthalmol
  doi: 10.1001/jamaophthalmol.2018.3789
– reference: 36822352 - J Am Acad Dermatol. 2023 May;88(5):1004
SSID ssj0001547371
Score 2.3731022
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 81
SubjectTerms bullous pemphigoid
Case Report
Dermatology
JAK inhibition
treatment
upadacitinib
Title Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2352512622005471
https://www.clinicalkey.es/playcontent/1-s2.0-S2352512622005471
https://dx.doi.org/10.1016/j.jdcr.2022.12.006
https://www.ncbi.nlm.nih.gov/pubmed/36691588
https://www.proquest.com/docview/2769375781
https://pubmed.ncbi.nlm.nih.gov/PMC9860157
https://doaj.org/article/f5e6ddf425be43abb9bf4cb6dfe8bbe5
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2352-5126
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001547371
  issn: 2352-5126
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2352-5126
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001547371
  issn: 2352-5126
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s3yqILEDUWQ2EmcI1StEKIVEiDtzfL4QV1QutrdcuS3800eq11A7YVLDomdx8znzDf2eEaIl6AEVJCOOTld5cpXNte29fBSXPSkg5Rtv1H4Y3Nyoufz9tNWqS-OCRvSAw-Cex2rUHsfAS0KSlqilqJyVPsYNFHos5eC9Ww5U8P-YNXI3tsqwTByWLV63DEzBHedecfJQMuynwvkckdbVqlP3r9jnP4mn3_GUG4ZpaM74vbIJrO3w1fcFddCd0_cPB7Xy--LA86uDd8-WwRoLX07Tz7rQ8uDz3gGNvtgO1z9njoYsyx1p4kwwpfZxcJ669I6dYkeiK9Hh18O3udj2YTcVbC3uVecoUZSrQoFoUkpiSwTlyiD8w4mScNuFRYj10Gy0IqKNfH6oS1Liz_gQ7HXnXfhschCFduWlH0TwQIimJTTUqtINfTRwvLPRDGJzbgxpziXtvhhpuCxM8OiNixqU5QGop6JV5s-iyGjxqWt37E2Ni05G3Z_AhgxI0bMVRiZCTnp0kwbTvGLxI3SpY9u_tUrrMZRvjKFWaGl-cwYY4iVPEUHaz8T1abnSGQGgnLlE19MQDMY5bx0Y7sAlJiSS1Zy6QHc-9EAvI1IZF1DF1rjfXcguSOz3StdOu0zibca_njVPPkfQn4qbuFT5BDR_kzsrZcX4bm44X6u02q5L643c73fD1Icj38d_gYuc0OP
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bullous+pemphigoid+treated+with+Janus+kinase+inhibitor+upadacitinib&rft.jtitle=JAAD+Case+Reports&rft.au=Nash%2C+David%2C+BHSc&rft.au=Kirchhof%2C+Mark+G.%2C+MD%2C+PhD&rft.date=2023-02-01&rft.issn=2352-5126&rft.eissn=2352-5126&rft.volume=32&rft.spage=81&rft.epage=83&rft_id=info:doi/10.1016%2Fj.jdcr.2022.12.006&rft.externalDBID=ECK1-s2.0-S2352512622005471&rft.externalDocID=1_s2_0_S2352512622005471
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23525126%2FS2352512622X00131%2Fcov150h.gif